New acetylcholinesterase inhibitor (donepezil) treatment for Alzheimer's disease in a chronic dialysis patient

Nephron
Junji SuwataMotoki Sano

Abstract

The new-generation acetylcholinesterase inhibitor, donepezil, is useful in the treatment of mild-to-moderate Alzheimer's disease. A 72-year-old male chronic hemodialysis patient was diagnosed as having moderate Alzheimer's disease. We administered donepezil at 3 mg/day orally to the patient. After 1 month's treatment, the patient improved to a controllable psychiatric condition and was discharged from the hospital. The 24-hour plasma concentration profile of donepezil following the 3-mg once-daily dose varied from 11.1 to 18.2 ng/ml. The through level of donepezil was reduced from 12.4 to 10.9 ng/ml over a 3-month period. We did not experience any episodes of drug toxicity or adverse effects in this chronic dialysis patient. Donepezil treatment might have a beneficial impact on patients with severe renal dysfunction.

Related Concepts

Eranz
Familial Alzheimer Disease (FAD)
Cholinesterase Inhibitors, Reversible
Hemodialysis
Indanones
Kidney Failure, Chronic
Piperidines

Related Feeds

Auditory Perception

Auditory perception is the ability to receive and interpret information attained by the ears. Here is the latest research on factors and underlying mechanisms that influence auditory perception.

© 2021 Meta ULC. All rights reserved